| Indication | limb-girdle muscular dystrophy Type 2I/R9 (LGMD2I/R9) |
| Drug | BBP-418 |
| Mechanism of Action | glycosylation substrate therapy |
| Company | BridgeBio Pharma |
| Trial Phase | Phase 3 |
| Trial Acronym | FORTIFY |
| NCT ID | NCT05775848 |
| Category | Regulatory Milestone |
| Sub Category | Approval Pending |
| Therapeutic Area | Rare Diseases & Genetics |
| FDA Action Date | Nov. 27, 2026 |
| Review Designation | Priority Review |
| Patient Population | 112 patients aged 12 to 60 years |
| Primary Interim Analysis Endpoint | Statistically significant increase in glycosylated αDG |
| Secondary Endpoints | Increase in glycosylated αDG and reduction in serum CK |
| Functional Outcome | 31-second difference in 100-meter time test vs. placebo |
| Peak Sales Projection | Greater than $1 billion annually |
| Orphan Drug Status | Granted by European Medicines Agency |
| Competitor Drug 1 | SRP-9003 (Sarepta Therapeutics) |
| Competitor Drug 2 | AB-1003 (Bayer’s AskBio) |
BridgeBio's BBP-418 Nears FDA Approval for LGMD2I/R9
BridgeBio Pharma's BBP-418 is nearing FDA approval for limb-girdle muscular dystrophy Type 2I/R9 (LGMD2I/R9), with an action date of Nov. 27, 2026. The oral glycosylation substrate therapy aims to increase FKRP, addressing the genetic mutation causing the disease. Data from the Phase 3 FORTIFY study, involving 112 patients, showed statistically significant increases in glycosylated αDG and reductions in serum CK, alongside meaningful functional improvements in walking and breathing. If approved, BBP-418 would be the first disease-modifying therapy for this rare condition, with analysts projecting over $1 billion in annual peak sales. The company is confident due to compelling evidence and unmet medical need, supported by priority review and no scheduled advisory committee meeting.
- Clinical Efficacy and Biomarker Data: The Phase 3 FORTIFY study met its primary interim analysis endpoint, demonstrating a statistically significant increase in glycosylated alpha-dystroglycan (αDG) in treated patients compared to placebo. Secondary endpoints also showed increased αDG and reduced serum CK, a biomarker for muscle damage. Exploratory 12-month data further indicated cardiac benefits, with all treated patients returning to normal range for HS troponin I, a heart muscle injury indicator.
- Functional Improvements and Patient Impact: BBP-418 led to meaningful functional gains, evidenced by a 31-second difference compared to placebo in a 100-meter time test after 12 months, which measures respiratory system muscle function. This improvement signifies a "real difference" for patients, potentially enabling independent ambulation and enhancing quality of life, as illustrated by a trial participant walking at her high school graduation.
- Regulatory Pathway and Market Potential: The FDA has set a Nov. 27, 2026, action date for BBP-418, supported by priority review and the absence of an advisory committee meeting, reflecting agency confidence. Positioned as the first disease-modifying therapy for LGMD2I/R9, it addresses a significant unmet need. Analysts project a market opportunity exceeding $1 billion annually at peak sales, with BridgeBio actively preparing its commercial launch infrastructure.
The Critical Need for New LGMD2I/R9 Therapies
Limb-Girdle Muscular Dystrophy R9 (LGMDR9) is a dystroglycanopathy caused by Fukutin-related protein (FKRP) defects leading to the deficiency of α-DG glycosylation, essential to membrane integrity. Currently there is no effective treatment available, and FKRP deficiency results in α-dystroglycan hypoglycosylation with progressive muscle injury and impaired function including loss of ambulation.
AAV-mediated FKRP gene therapy faces dose, distribution and quality-control hurdles. AAV gene therapy can achieve normal levels of transgene expression, but it requires high doses, with toxicity concerns and variable distribution. To demonstrate product activity, quality, and consistency throughout product and clinical development, regulatory authorities request several quality controls, including a potency assay aiming to demonstrate and quantify the intended biological effect of the gene therapy product.
Ribitol supplementation is constrained by residual enzyme dependence and limited restoration. Ribitol relies on residual FKRP function and restores limited levels of matriglycan. Ribitol as a pre-substrate of glycosyltransferase is able to compensate for the decreased function of mutant FKRP with restoration of matriglycan expression, but six months of treatment rescued functions dose-dependently and the only observed side effect was gastrointestinal tract bloating with loose stool and this effect is also dose dependent.
Supportive physiotherapy requires highly individualized, continuously monitored care with limited evidence. Diagnosing LGMD clinical variability is important, emphasizing the importance of precise subtype identification and tailoring therapy. Continuous monitoring and evaluation using appropriate scales and measurements are essential for tracking performance and tailoring treatment strategies, and regular follow-up consultations with the physiotherapist are needed to identify changes in an individual's health and alter the treatment plan accordingly.
Functional limitation and low activity further restrict non-pharmacologic management. There are few studies on possible effects of physiotherapy for adults with muscular dystrophy. Low functional ability was associated with physical inactivity in both LGMD and CMT, with participants with moderate to severe functional ability more likely to be physically inactive compared to those with normal functional ability (OR 19.7; 95% CI 3.1-127.2).
BBP-418's Compelling Efficacy and Safety in LGMD2I/R9
Recent studies in limb-girdle muscular dystrophy Type 2I/R9 (LGMD2I/R9) have focused on restoring α-dystroglycan glycosylation via metabolic precursors and on alternative mechanisms such as myostatin inhibition. The studies below span first-in-human healthy volunteer data, a single-patient case study, a preclinical dose-escalation model, and a phase Ib/IIa patient trial.
| Study | Intervention | Key Safety Outcomes | Key Efficacy Outcomes |
|---|---|---|---|
| Oral ribose supplementation in dystroglycanopathy: A single case study | Oral ribose supplementation during 6 months in a patient with limb girdle muscular dystrophy type 2I (LGMD2I) due to a homozygous FKRP mutation, doses of 9 g or 18 g/day | Ribose was well tolerated in doses of 9 g or 18 g/day | Supplementation with 18 g of ribose resulted in a decrease of creatine kinase levels of 70%; metabolomics showed a significant increase in CDP-ribitol levels with 18 g of ribose supplementation (p < 0.001); although objective improvement in clinical and patient-reported outcome measures was not observed, the patient reported subjective improvement of muscle strength, fatigue, and pain |
| Safety, Tolerability, Pharmacokinetics, Food Effect of Ribitol, and Its Effect on QTcF in Healthy Adults: First-in-Human, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled Studies | Ribitol administered as single or multiple oral doses over 6 days to healthy adults; therapeutic dose 9 and 12 g BID for patients weighing >30 to ≤50 kg and >50 kg, respectively | Ribitol was well tolerated when administered as single or multiple oral doses over 6 days to healthy adults; a dedicated QT study using ribitol 21 g revealed no concentration-dependent QTcF prolongation and clinically significant QTcF prolongation was excluded over the entire range of exposures in the study, up to 351.9 µg/mL | PK demonstrated dose-proportional increases in exposure from 0.5 to 15 g; t was 9-13 h; a high-fat meal did not affect overall oral bioavailability, indicating ribitol may be taken without regard to food intake |
| Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model | Dose-escalating efficacy study by gavage in P448L mutant mice; six months of ribitol treatment daily | The only observed side effect was gastrointestinal tract bloating with loose stool and this effect is also dose dependent | Six months of ribitol treatment daily significantly rescued functions of skeletal, respiratory, and cardiac muscles dose-dependently; associated with a dose dependent increase in matriglycan and improvement in muscle pathology with reductions in muscle degeneration, inflammatory infiltration and fibrosis; ribitol significantly increased life span and muscle functions of the female animals receiving treatment from 10 months of age |
| A phase Ib/IIa, open-label, multiple ascending-dose trial of domagrozumab in fukutin-related protein limb-girdle muscular dystrophy | Domagrozumab, a myostatin inhibitor, in one of three dosing arms (5, 20, or 40 mg/kg every 4 weeks); after 32 weeks of treatment, participants receiving the lowest dose were switched to the highest dose (40 mg/kg) for an additional 32 weeks | Domagrozumab was safe; the most frequently occurring adverse events were injuries secondary to falls | Serum concentrations of domagrozumab increased in a dose-dependent manner and modest levels of myostatin inhibition were observed in both serum and muscle tissue; there were no significant between-group differences in the strength, functional, or imaging outcomes studied; no clear evidence supporting its efficacy in improving muscle strength or function |
Frequently Asked Questions
References
- [1] Geoffroy M, Pili L et al.. CRISPR-Cas9 KO Cell Line Generation and Development of a Cell-Based Potency Assay for rAAV-FKRP Gene Therapy. Cells. 2023 Oct 12. 37887288
- [2] Yamamoto LU, Velloso FJ et al.. Muscle protein alterations in LGMD2I patients with different mutations in the Fukutin-related protein gene. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 2008 Nov. 18645206
- [3] Wang CH, Chan YM et al.. Post-Natal knockdown of fukutin-related protein expression in muscle by long-termRNA interference induces dystrophic pathology [corrected]. The American journal of pathology. 2011 Jan. 21224063
- [4] De Wel B, Huysmans L et al.. Prospective Natural History Study in 24 Adult Patients With LGMDR12 Over 2 Years of Follow-up: Quantitative MRI and Clinical Outcome Measures. Neurology. 2022 Aug 9. 35577579
- [5] Puckett RL, Moore SA et al.. Further evidence of Fukutin mutations as a cause of childhood onset limb-girdle muscular dystrophy without mental retardation. Neuromuscular disorders : NMD. 2009 May. 19342235
- [6] Lin YC, Murakami T et al.. A novel FKRP gene mutation in a Taiwanese patient with limb-girdle muscular dystrophy 2I. Brain & development. 2007 May. 17055682
- [7] Miller CL, Coffey LN et al.. Predicting Loss of Ambulation in Limb Girdle Muscular Dystrophy R9. Annals of clinical and translational neurology. 2026 Jun. 41486779
- [8] Severa G, Cortes-Rojas MC et al.. Case Report: Pediatric immune-mediated necrotizing myopathies mimicking inherited muscle disorders: clinical, paraclinical, and genetic insights from two cases. Frontiers in pediatrics. 2026. 42729513
- [9] Frattini P, Villa C et al.. Autologous intramuscular transplantation of engineered satellite cells induces exosome-mediated systemic expression of Fukutin-related protein and rescues disease phenotype in a murine model of limb-girdle muscular dystrophy type 2I. Human molecular genetics. 2017 Oct 1. 28666318
- [10] Willis E, Moore SA et al.. Limb-Girdle Muscular Dystrophy R9 due to a Novel Complex Insertion/Duplication Variant in FKRP Gene. Child neurology open. 2022 Jan-Dec. 35557983
- [11] Xu L, Lu PJ et al.. Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions. Molecular therapy : the journal of the American Society of Gene Therapy. 2013 Oct. 23817215
- [12] Wu B, Drains M et al.. Ribitol dose-dependently enhances matriglycan expression and improves muscle function with prolonged life span in limb girdle muscular dystrophy 2I mouse model. PloS one. 2022. 36454905
- [13] Muntoni F, Torelli S et al.. Muscular dystrophies due to glycosylation defects. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2008 Oct. 19019316
- [14] Silver JN, Elder M et al.. Recombinant adeno-associated virus-mediated gene transfer for the potential therapy of adenosine deaminase-deficient severe combined immune deficiency. Human gene therapy. 2011 Aug. 21142972
- [15] Prahm KP, Witting N et al.. Decreased variability of the 6-minute walk test by heart rate correction in patients with neuromuscular disease. PloS one. 2014. 25479403
- [16] Leung DG, Bocchieri AE et al.. Longitudinal functional and imaging outcome measures in FKRP limb-girdle muscular dystrophy. BMC neurology. 2020 May 19. 32429923
- [17] Kawahara G, Guyon JR et al.. Zebrafish models for human FKRP muscular dystrophies. Human molecular genetics. 2010 Feb 15. 19955119
- [18] Blaeser A, Awano H et al.. Progressive Dystrophic Pathology in Diaphragm and Impairment of Cardiac Function in FKRP P448L Mutant Mice. PloS one. 2016. 27711214
- [19] Leung DG, Bocchieri AE et al.. A phase Ib/IIa, open-label, multiple ascending-dose trial of domagrozumab in fukutin-related protein limb-girdle muscular dystrophy. Muscle & nerve. 2021 Aug. 33961310
- [20] Boito CA, Fanin M et al.. Biochemical and ultrastructural evidence of endoplasmic reticulum stress in LGMD2I. Virchows Archiv : an international journal of pathology. 2007 Dec. 17952692
Contact Us
Address
350 Springfield Avenue,
Suite #200 Summit, NJ 07901
For General Inquiry
info@pienomial.com
